Afferent Pharmaceuticals Announces The Election Of Dr. Peter Hirth To The Company's Board Of Directors

SAN MATEO, Calif.--(BUSINESS WIRE)--Afferent Pharmaceuticals, a leader in the development of small molecule compounds targeting P2X3 for the treatment of respiratory and urologic disorders as well as chronic pain, today announced the election of K. Peter Hirth, Ph.D., to Afferent's Board of Directors. Dr. Hirth has more than 30 years of drug discovery and development experience in the biotechnology and pharmaceutical industries, and has built several successful biotech companies.

Suggested Articles

The data, from two patients with severe blood disorders, are "promising” for what could be a one-and-done treatment, Cantor Fitzgerald analysts wrote.

The fund will back pharma companies as well as developers of medtech products and providers of outsourced services.

The money will fund work to develop polymers in multiple indications and an associated U.S. expansion.